Spots Global Cancer Trial Database for Biomolecular Analysis for Predicting Response to Regorafenib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Biomolecular Analysis for Predicting Response to Regorafenib
Official Title: Tumor Biomolecular Analysis for Defining Predictive Factors for Response to Regorafenib in Recurrent Glioblastoma
Study ID: NCT05759195
Interventions
Study Description
Brief Summary: The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, , Italy
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
